

# Assessment of Myocardial Metaiodobenzylguanidine Uptake and Its Relation to Left Ventricular Systolic and Diastolic Functional Parameters in Dilated Cardiomyopathy

Jong-Won Ha<sup>1</sup>, Jong-Doo Lee<sup>2</sup>, Namsik Chung<sup>1</sup>, Yangsoo Jang<sup>1</sup>, Sang-Ho Cho<sup>3</sup>, Byung-Soo Kim<sup>4</sup>  
Se-Joong Rim<sup>1</sup>, Won-Heum Shim<sup>1</sup>, Seung-Yun Cho<sup>1</sup>, and Sung-Soon Kim<sup>1</sup>

## Abstract

The purpose of this study was to assess the relation between myocardial metaiodobenzylguanidine (MIBG) uptake and left ventricular systolic and diastolic functional parameters, both of which are known as predictors of prognosis in patients with dilated cardiomyopathy. Echocardiography and iodine-123-MIBG myocardial scintigraphy were performed in 35 patients of dilated cardiomyopathy with normal sinus rhythm. Mean myocardial MIBG uptake in the patient group at early and delayed images were significantly lower than those in normal control subjects ( $10.6 \pm 1.1$ ,  $9.8 \pm 1.2$  vs  $12.4 \pm 1.0$ ,  $12.1 \pm 1.0$ ,  $p < 0.01$ ). There were, however, no significant differences of mean MIBG uptake in the lung and mediastinum between the two groups ( $p > 0.05$ ). There were no significant correlations between myocardial MIBG uptake, expressed as the ratio of heart/mediastinum MIBG activity at delayed image, and left ventricular systolic and diastolic functional parameters {left ventricular ejection fraction, left ventricular end-diastolic dimension, peak velocity of early diastolic filling (E velocity), deceleration time of E wave, cardiac output, left ventricular end-diastolic pressure}. In conclusion, the myocardial uptake of MIBG is decreased in patients with dilated cardiomyopathy assessed by iodine-123-MIBG myocardial scintigraphy. There were, however, no significant correlations between myocardial MIBG uptake and left ventricular systolic and diastolic functional parameters derived from echocardiography.

**Key Words:** Myocardial metaiodobenzylguanidine uptake, left ventricular systolic and diastolic function, dilated cardiomyopathy

## INTRODUCTION

The prognosis of patients with dilated cardiomyopathy is poor, with a 1-year mortality between 15 and 30%.<sup>1</sup> Cardiac transplantation emerged as an alternative treatment for the most severe patients who have no other option.<sup>2-4</sup> Unfortunately, a discrepancy exists between the number of candidates for heart transplantation and the availability of donors. Several studies have demonstrated a variety of prognostic

parameters using invasive or noninvasive diagnostic approaches.<sup>5-8</sup> Recently, the restrictive filling pattern, indicating severe diastolic dysfunction, was shown to be the best clinical predictor for cardiac deaths in patients with congestive heart failure and dilated cardiomyopathy.<sup>1,9</sup> Merlet et al. demonstrated that cardiac metaiodobenzylguanidine (MIBG) uptake assessed by iodine-123-MIBG myocardial scintigraphy and radionuclide left ventricular ejection fraction were the only predictors for survival in patients with congestive heart failure.<sup>10,11</sup> Thus, Doppler echocardiography and iodine-123-MIBG myocardial scintigraphy are regarded as useful non-invasive diagnostic modalities in assessing the prognosis in these patients. However, the relationship between myocardial MIBG uptake and echocardiographic variables reflecting left ventricular systolic and diastolic functions has not been well investigated. We analyzed cardiac MIBG imaging in patients with dilated cardiomyopathy and assessed the relation between left ventricular systolic

Received November 23, 1998

Accepted May 21, 1999

<sup>1</sup>Cardiology Division, <sup>2</sup>Department of Nuclear Medicine, <sup>3</sup>Department of Pathology, <sup>4</sup>Department of Applied Statistics, Yonsei University, Seoul, Korea

This study was presented in part at the European Association of Nuclear Medicine Congress, September, 1996, Copenhagen, Denmark.

Address reprint request to Dr. J. W. Ha, Cardiology Division, Yonsei Cardiovascular Center, Yonsei University College of Medicine, C.P.O. Box 8044, Seoul 120-752, Korea. Tel: 82-2-361-5836, Fax: 82-2-393-3035, E-mail: jwha@yumc.yonsei.ac.kr

and diastolic functional parameters derived from echocardiography and myocardial MIBG uptake.

## MATERIALS AND METHODS

### Subjects


Thirty-five patients (17 men and 18 women, mean age:  $53.6 \pm 14.3$ ) were included in this study. Ten healthy subjects served as controls. The diagnosis was based on a diagnostic procedure, including two-dimensional echocardiography, coronary angiography and left ventriculography. The diagnostic criteria were as follows: an enlarged left ventricle (M-mode echocardiographic left ventricular end-diastolic dimension  $> 55$  mm) with decreased systolic function (ejection fraction  $< 45\%$  by echocardiography), exclusion of ischemic heart disease, no history of hypertension, no clinical or histologic evidence of myocarditis or any other primary cause of cardiomyopathy, and no primary valvular disorder. The duration and severity of symptoms according to the New York Heart Association functional classification were assessed on the day of echocardiographic examination.

### Radionuclide ventriculography (RVG)

ECG-gated RVG was performed to assess the regional myocardial contractility and to measure left ventricular ejection fraction (LVEF). An injection of 1 mg of pyrophosphate, 20 mCi (740 MBq) of Tc-99m-pertechnetate was administered to the antecubital vein 30 minutes later. Anterior, left anterior oblique (LAO) and lateral views at preset 1000 K counts were obtained. R-R interval was divided into 24 frames. The LVEF was measured manually by drawing a ROI over the left ventricle on LAO view. The regional wall motion was assessed visually.

### Iodine-123-MIBG scintigraphy

Before scintigraphy, 100 mg of potassium iodide solution was given for at least 5 consecutive days (2 days before and 3 days after the scintigraphy) to block thyroid uptake. All medications were discontinued 24 hours before scintigraphy. The thirty minutes and 4 hours after injection of 3 mCi (111 MBq) of iodine-123-MIBG (Daichi Lab, Japan), planar and



*Fig. 1. Anterior planar image of iodine-123-MIBG scintigraphy. Regions of interest were drawn over the lung (L), mediastinum (M), and the heart (H). Mean counts per pixel in each of the areas were obtained, and heart to mediastinal activity ratios were calculated.*

SPECT images were obtained. Planar anterior views were acquired at a preset count of 200K on a dual-headed gamma camera equipped with low energy high resolution parallel-hole collimators (ADAC, Milpitas, USA) in  $64 \times 64$  matrices. A 20% of energy window centered on 159 KeV was used for imaging. SPECT images were obtained at 40 sec/view with 5.6 degree of angular increment and projection data were reconstructed by the filtered back projection method using a butterworth filter (Nyquist frequency 0.35 cycle/cm, order No.5). Short axis, vertical long axis and horizontal long axis views were then obtained by reorientation of transaxial images. SPECT findings were assessed visually to evaluate the presence of adrenergic neuronal damage. On planar views, the region of interest (ROI) was drawn over the lung, mediastinum and heart (Fig. 1). MIBG uptake of the heart, lung and mediastinum was measured as a count per pixel. Mean MIBG uptake was expressed as (early uptake + delayed uptake)/2. The heart-to-lung (H/L) and heart-to-mediastinal (H/M) activity ratios were also calculated from early and delayed images.

### Echocardiographic analysis

M-mode, two-dimensional and pulsed wave Doppler echocardiographic examinations were performed



dynamics, which is characterized by shortened DT and increased E/A ratio.

### Radionuclide ventriculography

Left ventricular ejection fraction was decreased in the patient group ( $25.5 \pm 9.2\%$ ). Regional wall motion abnormality was not observed in all patients.

### Hemodynamic findings and myocardial biopsy results

Right heart catheterization was performed in 14 patients. Mean left ventricular end-diastolic pressure and mean pulmonary artery pressure were  $19.7 \pm 6.4$  mmHg and  $24.5 \pm 9.1$  mmHg, respectively (Table 2). Endomyocardial biopsy was performed in 9 patients. Light microscopic examination of biopsy specimens revealed various degrees of fibrosis and myocyte hypertrophy without inflammatory infiltrates or other pathognomonic findings.

### 24-hr urinary catecholamine measurements

Twenty-four hour urinary concentration of epinephrine and norepinephrine in the patient group were  $23.9 \pm 30.6$  ug and  $80.8 \pm 120.8$  ug, respectively.

Table 1. Echocardiographic Variables in Patient Group (N=35)

LVEDD (mm)	$69.4 \pm 7.1$
LVESD (mm)	$61.8 \pm 7.8$
LVEF (%)	$23.7 \pm 8.0$
LVFS (%)	$11.1 \pm 4.7$
MR grade I/II/III/IV	13/9/4/1
TR grade I/II/III/IV	16/4/2/1
E velocity (m/sec)	$0.80 \pm 0.30$
A velocity (m/sec)	$0.56 \pm 0.28$
E/A ratio	$2.2 \pm 2.3$
Deceleration time (msec)	$178.8 \pm 91.2$
IVRT (msec)	$105.2 \pm 29.4$

Values are mean  $\pm$  SD or number of subjects. A indicates peak velocity of late diastolic filling wave; E, peak velocity of early diastolic filling wave; IVRT, isovolumic relaxation time; LVEDD, left ventricular end-diastolic dimension; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic dimension; LVFS, left ventricular fractional shortening; MR, mitral regurgitation; TR, tricuspid regurgitation.

### Iodine-123-MIBG scintigraphy

Mean myocardial MIBG uptake in the patient group at early and delayed images were significantly lower than that in normal control subjects ( $10.6 \pm 1.1$ ,  $9.8 \pm 1.2$  vs  $12.4 \pm 1.0$ ,  $12.1 \pm 0.9$ ,  $p < 0.01$ ). There were, however, no significant differences of mean MIBG uptake of lung and mediastinum between the two groups ( $p > 0.05$ ). The early and delayed heart/lung ratios in the patient group were significantly lower than those in normal control subjects ( $0.9 \pm 0.1$ ,  $1.0 \pm 0.1$  vs  $1.2 \pm 0.2$ ,  $1.3 \pm 0.1$ ,  $p < 0.01$ ). The early and delayed heart/mediastinum ratios in patient group were also significantly lower than those in normal control subjects ( $1.6 \pm 0.2$ ,  $1.5 \pm 0.2$  vs  $2.0 \pm$

Table 2. Hemodynamic Variables in Patient Group (N=14)

PCWP (mmHg)	$17.9 \pm 8.6$
MPASP (mmHg)	$36.3 \pm 12.7$
MPADP (mmHg)	$18.5 \pm 8.3$
MPAMP (mmHg)	$24.5 \pm 9.1$
RVSP (mmHg)	$38.9 \pm 12.2$
RAP (mmHg)	$7.8 \pm 6.1$
LVEDP (mmHg)	$19.7 \pm 6.4$

LVEDP indicates left ventricular end-diastolic pressure. MPADP, main pulmonary artery diastolic pressure; MPASP, main pulmonary artery systolic pressure; MPAMP, main pulmonary artery mean pressure; PCWP, pulmonary capillary wedge pressure; RAP, right atrial pressure; RVSP, right ventricular systolic pressure.

Table 3. Early and Delayed MIBG Uptake of Heart, Lung, and Mediastinum in Patients and Normal Control Groups

	Patient (N=35)	Control (N=10)	p value
Early Heart	$10.6 \pm 1.1$	$12.4 \pm 1.0$	0.006
Early Lung	$11.8 \pm 1.5$	$10.5 \pm 1.1$	0.100
Early mediastinum	$6.5 \pm 0.6$	$6.8 \pm 1.3$	0.407
Delay Heart	$9.8 \pm 1.2$	$12.1 \pm 0.9$	0.000
Delay Lung	$10.2 \pm 1.1$	$10.3 \pm 1.2$	0.716
Delay Mediastinum	$6.3 \pm 0.5$	$6.8 \pm 1.1$	0.163
Early H/L	$0.9 \pm 0.1$	$1.2 \pm 0.2$	0.015
Delay H/L	$1.0 \pm 0.1$	$1.3 \pm 0.1$	0.001
Early H/M	$1.6 \pm 0.2$	$2.0 \pm 0.1$	0.000
Delay H/M	$1.5 \pm 0.2$	$2.0 \pm 0.1$	0.000

H, heart; L, lung; M, mediastinum.



0.1,  $2.0 \pm 0.1$ ,  $p < 0.001$ ) (Table 3). The early and delayed heart/mediastinum ratios of patients with NYHA functional class 3 and 4 were significantly lower than those in patients with NYHA functional class 1 and 2 ( $p < 0.01$ ). There were, however, no significant differences of early and delayed heart/mediastinum ratios of MIBG uptake between the two groups separated by diastolic left ventricular filling pattern (relaxation abnormality vs restrictive hemodynamic).

### Correlation between myocardial MIBG uptake and left ventricular functional parameters

There were no significant correlations between myocardial MIBG uptake, expressed as delayed heart/mediastinum ratio, and left ventricular end-diastolic dimension, cardiac output, left ventricular ejection fraction, E velocity, DT of E wave and left ventricular end-diastolic pressure (Fig. 3-8).

## DISCUSSION

The principal findings of the present study were that (1) myocardial MIBG uptake was reduced in patients with dilated cardiomyopathy, and (2) there were no significant correlations between myocardial MIBG uptake, expressed as delayed heart/mediastinum ratio which is known as a strong predictor of prognosis, and left ventricular diastolic functional parameters derived from echocardiography, which are also independent prognostic indicators.

Previous investigations have shown that the prognosis of patients with congestive heart failure appears inversely related to the levels of circulating norepinephrine, which reflect the magnitude of neurohormonal activation.<sup>14,15</sup> Heart failure is a predominant clinical feature of dilated cardiomyopathy. Heart failure is accompanied by important disturbances of the autonomic nervous system.<sup>16-21</sup> Plasma norepinephrine, however, is derived from adrenergic activity throughout the body and is therefore not a specific index of cardiac adrenergic activity.<sup>22-24</sup> Microelectrodes in the superficial nerves innervating muscle or skin or recording potential effector responses to neurally-released norepinephrine can be used in the assessment of sympathetic function in humans.<sup>25</sup> Each of these methods, however, assesses different aspects of sym-

pathetic function and has its advantages and limitations. Recently, a more direct, noninvasive and qualitative assessment of cardiac sympathetic nervous integrity has been possible with iodine-123-MIBG, a guanethidine analog that shares many neuronal transport and storage mechanisms with norepinephrine.<sup>26-28</sup> Abnormalities in myocardial MIBG uptake have been related to sympathetic denervation in the setting of left ventricular damage or dysfunction associated with myocardial infarction, or dilated cardiomyopathy.<sup>29-31</sup> Schofer et al. reported iodine-123-MIBG imaging in 31 patients with dilated cardiomyopathy and showed that the myocardial versus mediastinal MIBG activity ratio was related to myocardial norepinephrine concentration and to left ventricular ejection fraction.<sup>32</sup> Glowniak et al. reported decreased uptake of MIBG within the heart in patients with idiopathic congestive cardiomyopathy suggesting cardiac sympathetic nerve dysfunction.<sup>30</sup> Our data also demonstrated that myocardial MIBG uptake is reduced in patients with dilated cardiomyopathy and this is consistent with previous studies. However, in contrast to the study of Schofer et al.<sup>32</sup> there is only a weak correlation between left ventricular ejection fraction and myocardial MIBG uptake. The quantity of norepinephrine released by adrenergic nerve endings in the heart is, under ordinary circumstances, dependent on the adrenergic impulse traffic, and alterations in the frequency of nerve impulses modify the quantity of norepinephrine released and acting on beta-adrenergic receptors in the myocardium. This mechanism is the most important one which acutely modifies the position of the force-velocity and ventricular function curves under physiologic conditions. Simmons et al. demonstrated that the MIBG heart-to-lung ratio was positively correlated with left ventricular tissue norepinephrine content in a canine pacing-induced heart failure model.<sup>33</sup> However, no relation was found between plasma norepinephrine concentration and the heart/lung MIBG ratio. Although, no significant relation was found between myocardial MIBG uptake and systolic functional parameters, such as ejection fraction and cardiac output in our study, it can be speculated that left ventricular contractile reserve could be related to myocardial MIBG uptake. Therefore it is conceivable that myocardial MIBG uptake will be more closely related to left ventricular contractile reserve than with resting left ventricular systolic functional indices such

as ejection fraction. Further studies are needed to consolidate this issue.

Assessment of left ventricular diastolic function by Doppler echocardiographic analysis of the diastolic transmitral inflow have been regarded as a useful noninvasive diagnostic modality in predicting the prognosis of patients with congestive heart failure including dilated cardiomyopathy. Werner et al. reported that deceleration time and peak early Doppler velocity were the strongest predictors of survival as compared with systolic function and clinical status in a Cox proportional hazards analysis.<sup>1</sup> It has also been demonstrated that restrictive left ventricular filling pattern in patients with dilated cardiomyopathy is a powerful indicator of increased mortality risk.<sup>9</sup> Similar results were reported in patients with congestive heart failure.<sup>34</sup> However, myocardial MIBG uptake was not evaluated in these studies, thus an assessment of correlation between two variables, which had been known as independent prognostic factors, cannot be made. In this study, we analyzed the correlation between variables which were known to be related to the prognosis in congestive heart failure derived from two different noninvasive diagnostic modalities and demonstrated no significant relation between myocardial MIBG uptake and diastolic functional parameters derived from Doppler echocardiography. Imamura et al. assessed myocardial adrenergic activity using iodine-123-MIBG imaging in patients with heart failure from various causes and demonstrated that there was no correlation between myocardial MIBG washout and diastolic function.<sup>35</sup> In their study, diastolic function was analyzed by peak filling rate and time to peak filling rate derived from a time activity curve of gated radionuclide angiography.

In conclusion, the results from our study suggested that myocardial MIBG uptake, expressed as the ratio of heart/mediastinum MIBG activity at delayed image, reflects a different aspect of prognosis in patients with dilated cardiomyopathy, which is not closely related to left ventricular systolic and diastolic functional parameters.

## ACKNOWLEDGMENTS

We are very grateful to Ji-Young Kim, Eun-Kyung Oh, Eun-Kyung Hwang, Hyun-Joo Kim and Eui-Sun Ryu at the echocardiography laboratory for

technical assistance in this study. We also thank Jung-Hoon Kim, Hyun-Ah Yang and Hye-Jin Kim for secretarial assistance in preparation of the manuscript.

## REFERENCES

1. Werner GS, Schaefer C, Dirks R, Figulla HR, Kreuzer H. Prognostic value of Doppler echocardiographic assessment of left ventricular filling in idiopathic dilated cardiomyopathy. *Am J Cardiol* 1994;73:792-8.
2. Barnard CN. A human cardiac transplant: an interim report of a successful operation performed at Groote Schuur Hospital, Cape Town. *S Afr Med J* 1967;41:1271-4.
3. Copeland JG, Stinson EB. Human heart transplantation. *Curr Probl Cardiol* 1979;4:1-5.
4. Pennock JL, Oyer PE, Reitz BA, Jamieson SW, Bieber CP, Wallwork J, et al. Cardiac transplantation in perspective for the future. *J Thorac Cardiovasc Surg* 1982;83:168-77.
5. Unverferth DV, Magorien RD, Moeschberger ML, Baker PB, Fettes JK, Leier CV. Factors influencing the one year mortality of dilated cardiomyopathy. *Am J Cardiol* 1984;54:147-52.
6. Juilliere Y, Danchin N, Briacon S, Khalife K, Ethevenot G, Balaud A, et al. Dilated cardiomyopathy: Long-term follow-up and predictors of survival. *Int J Cardiol* 1988;21:269-77.
7. Romeo F, Pelliccia F, Cianfrocca C, Gallo P, Barrila F, Critofani R, et al. Determinants of end stage idiopathic dilated cardiomyopathy: a multivariate analysis of 104 patients. *Clin Cardiol* 1989;12:387-92.
8. Stevenson LW, Fowler MB, Schroeder JS, Stevenson WG, Dracup KA, Fond V. Poor survival of patients with idiopathic dilated cardiomyopathy considered too well for transplantation. *Am J Cardiol* 1994;73:792-8.
9. Pinamonti B, Di Lenarda A, Sinagra G, Camerini F. Restrictive left ventricular filling pattern in dilated cardiomyopathy assessed by Doppler echocardiography: Clinical, echocardiographic and hemodynamic correlations and prognostic implications. *J Am Coll Cardiol* 1993;22:808-15.
10. Merlet P, Vallette H, Dubois-Rande J, Moyse D, Duboc D, Dove P, et al. Prognostic value of cardiac metaiodobenzylguanidine imaging in patients with heart failure. *J Nucl Med* 1992;33:471-7.
11. Merlet P, Benvenuti C, Dubois-Rande J, Poullart F, Vallette H, Duboc D, et al. Cardiac I-123 metaiodobenzylguanidine imaging as a prognostic guide in congestive heart failure. *Circulation* 1993;88:I-257.
12. American Society of Echocardiography Committee on Standards. Recommendations for quantification of the left ventricle by two-dimensional echocardiography. *J Am Soc Echocardiogr* 1989;2:358-67.
13. Helmcke F, Nanfa NC, Hsiung MC, Soto B, Adey CK,

- Goyal RG, et al. Color Doppler assessment of mitral regurgitation with orthogonal planes. *Circulation* 1987;75:175-83.
14. Cohn JN, Levine TB, Olivari V, Garberg D, Lura GS, Francis A, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. *N Engl J Med* 1987;316:1429-35.
15. Cohn JN, Simon A, Johnson G, and the V-HeFT Study Group. Relationship of plasma norepinephrine and plasma renin activity to mortality in heart failure: V-HeFT II. *Circulation* 1991;84 Suppl II:II-310.
16. Thomas JA, Marks BH. Plasma norepinephrine in congestive heart failure. *Am J Cardiol* 1978;41:233-43.
17. Levine TB, Francis GS, Goldsmith SR, Simon AB, Cohn JN. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relationship to hemodynamic abnormalities in congestive heart failure. *Am J Cardiol* 1982;49:1659-66.
18. Hansking GJ, Esler MD, Jennings GL, Burton D, Korner PI. Norepinephrine spillover to plasma in patients with congestive heart failure evidence of increased overall and cardiorenal sympathetic nervous activity. *Circulation* 1986;73:615-21.
19. Creager MA, Faxon DP, Cutler SS, Kohlmann O, Ryan TJ, Gavras H. Contribution of vasopressin to vasoconstriction in patients with congestive heart failure: comparison with the renin-angiotensin system and the sympathetic nervous system. *J Am Coll Cardiol* 1986;7:758-65.
20. Burnett JC Jr, Kao PC, Hu DC, Heser DW, Heublein D, Granger JP, et al. Atrial natriuretic peptide elevation in congestive heart failure in the human. *Science* 1986;231:1145-7.
21. Hirsch AT, Creager MA, Dzau VJ. Relation of atrial natriuretic factor to vasoconstrictor hormones and regional blood flow in congestive heart failure. *Am J Cardiol* 1989;63:211-6.
22. Folkow B, DiBona GF, Hjendahl P, Toren PH, Wallin BG. Measurements of plasma norepinephrine concentrations in human primary hypertension: a word of caution on their applicability for assessing neurogenic contributions. *Hypertension* 1983;5:399-403.
23. Floras JS, Jones JV, Hassan MO, Osikowska BA, Sever PS, Sleight P. Failure of plasma norepinephrine to consistently reflect sympathetic activity in man. *Hypertension* 1986;8:641-9.
24. Esler M, Jennings G, Korner P, Willett I, Dudley F, Hasking G, et al. Assessment of human sympathetic nervous system activity from measurement of norepinephrine turnover. *Hypertension* 1988;11:3-20.
25. Wallin BG, Fagius J. Peripheral sympathetic neural activity in conscious humans. *Ann Rev Physiol* 1988;50:565-76.
26. Sisson JC, Wieland DM, Shermen P, Manger TJ, Tobes MC, Jacques S Jr. Metaiodobenzylguanidine as an index of the adrenergic nervous system integrity and function. *J Nucl Med* 1987;28:1620-4.
27. Sisson JC, Shapiro B, Meyers L, Mallette S, Mangner TJ, Wieland DM, et al. Metaiodobenzylguanidine to map scintigraphically the adrenergic system in man. *J Nucl Med* 1987;28:1625-36.
28. Dae MW, O'Connell JW, Borvinick EH, Ahearn T, Yee E, Huberty JP, et al. Scintigraphic assessment of regional cardiac adrenergic innervation. *Circulation* 1989;79:634-44.
29. Henderson EB, Kahn JK, Corbett JR, Jansen DE, Pippin JJ, Kulkarni P, et al. Abnormal I-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy. *Circulation* 1988;78:1192-9.
30. Glowniak JV, Turner FE, Gray LL, Palac RT, Lagunas-Solar MC, Woodward WR. Iodine-123-metaiodobenzylguanidine imaging of the heart in idiopathic congestive cardiomyopathy and cardiac transplants. *J Nucl Med* 1989;30:1182-91.
31. McGhie AL, Corbett JR, Akers MS, Kulkarni SMN, Kremers M, Buja LM, et al. Regional cardiac adrenergic function using I-123-meta-iodobenzylguanidine tomographic imaging after myocardial infarction. *Am J Cardiol* 1991;67:236-42.
32. Schofer J, Spielman R, Schuchert A, Weber K. I-123-metaiodobenzylguanidine (MIBG) scintigraphy: A noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. *J Am Coll Cardiol* 1988;12:1252-8.
33. Simmons WW, Freeman MR, Grima EA, Hsia TW, Armstrong PW. Abnormalities of cardiac sympathetic function in pacing-induced heart failure as assessed by 123-I-metaiodobenzylguanidine scintigraphy. *Circulation* 1994;89:2843-51.
34. Xie GY, Berk MR, Smith MD, Gurley JC, DeMaria AN. Prognostic value of Doppler transmitral flow pattern in patients with congestive heart failure. *J Am Coll Cardiol* 1994;24:132-9.
35. Imamura Y, Ando H, Mitsuoka W, Egashira S, Masaki H, Ashihara T, Fukuyama T. Iodine-123 metaiodobenzylguanidine images reflect intense myocardial adrenergic nervous activity in congestive heart failure independent of underlying cause. *J Am Coll Cardiol* 1995;26:1594-9.